CBUS

Cibus Inc

Add to Watchlist

Advanced Chart

1.610

-0.04(-2.424%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.7494

Open

1.700

VWAP

1.62

Vol

141.52K

Mkt Cap

80.64M

Low

1.600

Amount

228.90K

EV/EBITDA(TTM)

Total Shares

22.91M

61.36M

EV/OCF(TTM)

P/S(TTM)

9.07

Cibus, Inc. is an agricultural technology company that uses gene-editing technologies to develop plant traits in seeds. Its business is the development of plant traits for some of the agricultural food crops that help address specific productivity, profitability, sustainability, or yield challenges in farming. Its core technology propriety gene editing platform is called the Rapid Trait Development System (RTDS). It is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. It has a pipeline of five productivity traits. It has developed the productivity trait Pod Shatter Reduction (PSR) in Canola and Winter Oilseed Rape (WOSR) strengthens the sheath around the canola seeds. Its advanced productivity traits, Sclerotinia resistance and HT2 in Canola and WOSR, continue to progress and offer white mold disease resistance and broadleaf weed herbicide tolerance.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

1.71M

+41.03%

1.51M

-9.32%

1.15M

+36.71%

Estimates Revision

The market is revising Downward the revenue expectations for Cibus, Inc. (CBUS) for FY2025, with the revenue forecasts being adjusted by -35.43% over the past three months. During the same period, the stock price has changed by -19.50%.

Revenue Estimates for FY2025

Revise Downward

-35.43%

In Past 3 Month

Stock Price

Go Down

-19.50%

In Past 3 Month

3 Analyst Rating

1214.91% Upside

Wall Street analysts forecast CBUS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CBUS is 21.17 USD with a low forecast of 15.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

1214.91% Upside

Current: 1.610

Low

15.00

Averages

21.17

High

25.00

1214.91% Upside

Current: 1.610

Low

15.00

Averages

21.17

High

25.00

Canaccord

Austin Moeller

Buy

downgrade

$18

2025-05-12

Reason

Canaccord

Austin Moeller

Price Target

$18

2025-05-12

downgrade

Buy

Reason

Canaccord analyst Austin Moeller lowered the firm's price target on Cibus to $17.50 from $18 and keeps a Buy rating on the shares. The firm noted Cibus is not yet generating meaningful commercial revenues at this point in the company's lifecycle. However, through contract research on behalf of customers relating to collaborative agreements for products and traits, the company has consistently generated some quarterly revenue in advance of major trait commercializations. Cibus' nearest-term revenue-generation opportunity continues is its sustainable ingredients biofragrance product pipeline.

HC Wainwright & Co.

Amit Dayal

Strong Buy

Reiterates

$25

2025-03-21

Reason

HC Wainwright & Co.

Amit Dayal

Price Target

$25

2025-03-21

Reiterates

Strong Buy

Reason

Canaccord Genuity

Austin Moeller

Strong Buy

Maintains

$20 → $18

2025-01-22

Reason

Canaccord Genuity

Austin Moeller

Price Target

$20 → $18

2025-01-22

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Amit Dayal

Strong Buy

Reiterates

$25

2024-11-11

Reason

HC Wainwright & Co.

Amit Dayal

Price Target

$25

2024-11-11

Reiterates

Strong Buy

Reason

Canaccord Genuity

Austin Moeller

Strong Buy

Maintains

$20

2024-10-22

Reason

Canaccord Genuity

Austin Moeller

Price Target

$20

2024-10-22

Maintains

Strong Buy

Reason

Alliance Global Partners

Matthew Venezia

Strong Buy

Maintains

$25 → $24

2024-09-24

Reason

Alliance Global Partners

Matthew Venezia

Price Target

$25 → $24

2024-09-24

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Cibus Inc (CBUS.O) is -0.89, compared to its 5-year average forward P/E of -3.42. For a more detailed relative valuation and DCF analysis to assess Cibus Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.42

Current PE

-0.89

Overvalued PE

-0.99

Undervalued PE

-5.84

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.13

Current EV/EBITDA

-3.73

Overvalued EV/EBITDA

-1.01

Undervalued EV/EBITDA

-7.24

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

56.07

Current PS

11.09

Overvalued PS

139.57

Undervalued PS

-27.43

Financials

Annual

Quarterly

FY2025Q1

YoY :

+89.72%

1.03M

Total Revenue

FY2025Q1

YoY :

+11.75%

-20.62M

Operating Profit

FY2025Q1

YoY :

+83.12%

-49.39M

Net Income after Tax

FY2025Q1

YoY :

+19.64%

-1.34

EPS - Diluted

FY2025Q1

YoY :

-11.60%

-12.12M

Free Cash Flow

FY2025Q1

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2025Q1

YoY :

-54.80%

-1.21K

FCF Margin - %

FY2025Q1

YoY :

-3.48%

-4.78K

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

47.4K

USD

6-9

Months

188.3K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

47.4K

USD

6-9

Months

188.3K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

CBUS News & Events

Events Timeline

2025-07-23 (ET)

2025-07-23

17:03:52

Cibus announces reduction in force

2025-06-24 (ET)

2025-06-24

07:04:07

Cibus completed U.S. FDA's Plant Biotech Consultation program

2025-06-12 (ET)

2025-06-12

08:05:28

Cibus, John Innes Centre confirm continuing collaboration

News

9.0

06-24Newsfilter

The U.S. Food and Drug Administration Completes Review of Cibus' Altered Lignin Alfalfa Developed in Partnership with S&W Seed Company for use in Livestock Feed

7.5

06-12Newsfilter

Cibus and John Innes Centre Announce Ongoing Collaboration with Potential to Revolutionize Fertilizer Use in Farming

8.5

06-10Newsfilter

Cibus, Inc. Announces Closing of $27.5 Million Public Offering